SMITHS-DETECTION
13.4.2021 13:02:12 CEST | Business Wire | Press release
Smiths Detection, a global leader in threat detection and security screening technologies, today announces that its BioFlash® Biological Identifier has been successfully used by the University of Maryland, Baltimore County (UMBC) to identify airborne SARS-CoV-2 inside their campus in real-time at the point of testing.
As part of their mitigation strategy for COVID-19, UMBC’s Environmental Safety and Health (ESH) team have been using BioFlash across the campus. In one instance, the airborne detector was deployed to help the campus community safely re-enter a research facility after a person working there tested positive. After multiple tests performed on the BioFlash ruled-out the presence of airborne SARS-CoV-2, the ESH team deemed the facility contamination-free, allowing staff and students to safely return and research to continue without significant pause.
In a separate instance, in a collaborative effort with the UMBC Sports Medicine Department, a test conducted in a team locker room resulted in a positive environmental detection on the BioFlash. This detection ultimately led UMBC to test all people present for COVID-19, identifying three infected individuals. This helped prevent further spread of the virus.
“We are delighted to see what we believe is a world-first for our technology. BioFlash, with its real-time results capability, has been used by UMBC in a real-world setting to successfully confirm the presence or absence of COVID-19 in the air and inform health and safety protocols,” said Smiths Detection President Roland Carter. “We have been working incredibly hard to provide a tool that will support the ongoing fight against COVID-19, and these applications demonstrate the role BioFlash can play in virus mitigation strategies.”
“The BioFlash system has helped us to prevent the spread of the virus in our on-campus community. We are also pleased that this tool to protect the health and safety of people on our campus is easy to use and environmentally friendly,” said Lynne Schaefer, UMBC Vice President for Administration and Finance . “We will be using this solution as part of a larger mitigation strategy, alongside other important tools like sanitation, masks, regular testing, physical distancing, and symptom monitoring.”
BioFlash works by collecting and analysing air samples using sensitive, selective and rapid detection technology to identify the presence of dangerous pathogens onsite without the need to involve a laboratory. Following successful internal testing, Smiths Detection has been engaged in various external studies to further verify the SARS-CoV-2 detection capability, including working with the USAMRIID, which verified that BioFlash could identify SARS-CoV-2 in a laboratory setting.
The BioFlash Biological Identifier is available now.
ENDS
About BioFlash Biological Identifier
The BioFlash ® Biological Identifier is a bio-aerosol collection and identification system that provides rapid, sensitive and specific identification of various pathogens including viruses, toxins and bacteria. The BioFlash has been commercially available for over 10 years and is currently used by US government and commercial clients for a number of applications.
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, defence and urban security markets. Our experience and history across more than 40 years at the frontline enables us to deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
For more information visit http://www.smithsdetection.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005091/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom